Skip to content

Research Explainer

Are GLP-1 medicines safe? What the studies report.

Safety depends on the person, the medicine, and the product. Here is what two large trials reported about side effects—and where questions remain.

What STEP 1 reported

In a 68-week trial of 1,961 adults taking semaglutide or placebo, nausea and diarrhea were the most common adverse events. Gastrointestinal events led 4.5% of semaglutide participants and 0.8% of placebo participants to stop treatment.[1]

What SURMOUNT-1 reported

In a 72-week trial of 2,539 adults taking tirzepatide or placebo, the most common adverse events were gastrointestinal and largely mild to moderate, mainly during dose escalation.[2]

Product quality matters too

FDA says unapproved versions of these medicines do not undergo FDA review for safety, effectiveness, or quality before they are marketed.[3]

What’s still being studied

WHO’s 2025 guideline made its recommendation conditional, citing limited data on long-term efficacy and safety.[4]

What this does not answer

It does not tell any one person whether a medicine is right or safe for them. Individual decisions and support needs belong with a qualified healthcare professional.

This page is for general education and event programming. It does not provide medical advice, diagnose conditions, recommend treatment, or endorse a medication, provider, product, or service.

Sources

  1. [1]Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)New England Journal of MedicineRead the source (opens in a new tab)
  2. [2]Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)New England Journal of MedicineRead the source (opens in a new tab)
  3. [3]FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight LossU.S. Food & Drug AdministrationRead the source (opens in a new tab)
  4. [4]WHO issues global guideline on the use of GLP-1 medicines in treating obesityWorld Health OrganizationRead the source (opens in a new tab)